Pneumococcal 20-valent Conjugate Vaccine

BIOLOGICAL4 trials

Sponsors

University of Utah, Vaxcyte, Inc., Seema Bhat, Pfizer

Conditions

Chronic Lymphocytic LeukemiaPneumococcal ImmunizationPneumococcal VaccinesSafetySmall Lymphocytic Lymphoma

Phase 2

Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial

RecruitingNCT05183854

University of UtahChronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Start: 2022-01-31End: 2028-06-01Target: 60Updated: 2026-02-17

Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults

CompletedNCT05297578

Vaxcyte, Inc.Pneumococcal Vaccines

Start: 2022-06-15End: 2023-02-15Updated: 2024-10-09

Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia

RecruitingNCT05417165

Seema BhatChronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Start: 2023-09-29End: 2026-10-31Target: 80Updated: 2026-01-07

Unknown Phase

A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market

RecruitingNCT06760208

PfizerPneumococcal Immunization, Safety

Start: 2025-11-13End: 2027-03-01Target: 660Updated: 2026-03-12

Related Papers

A phase 2, randomized, blinded, dose-finding, controlled clinical trial to evaluate the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults 65 years and older

Vaccine2024-07-179 citations